Neurogene Inc.
NGNE
$29.82
-$1.45-4.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -25.06% | -18.05% | 4.83% | 2.79% | -16.06% |
| Total Depreciation and Amortization | 8.51% | 1.42% | 1.17% | 0.66% | -4.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -12.08% | 63.96% | -11.61% | -13.35% | 19.33% |
| Change in Net Operating Assets | -64.96% | 364.66% | -215.46% | 71.64% | -57.81% |
| Cash from Operations | -49.86% | 10.66% | -0.24% | 6.32% | -18.74% |
| Capital Expenditure | -119.53% | -0.79% | 14.19% | 81.03% | -572.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 56.44% | 34.45% | 191.09% | 117.16% | 56.81% |
| Cash from Investing | 56.17% | 34.65% | 195.17% | 116.54% | 56.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 68.42% | -46.15% | 7.14% | 6.67% | -15.38% |
| Issuance of Common Stock | -99.03% | 109.87% | 14,442.65% | 257.89% | -99.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 54.82% | -- | -- | -- |
| Cash from Financing | -99.06% | 112.77% | 17,881.48% | 1,250.00% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -38.14% | 169.36% | 201.96% | 81.83% | -194.08% |